Kalbe Farma, Owned By Conglomerate Boenjamin Setiawan, Presents The Latest Genetic Examination In Indonesia

JAKARTA - The pharmaceutical company owned by conglomerate Boenjamin Setiawan, PT Kalbe Farma Tbk (KLBF) through its subsidiary, PT Bifarma Adiluhung, presents the latest genetic tests in Indonesia, namely KiddyGENME and PrimeGENME.

These two examinations can analyze DNA variations related to child growth and development as well as the risk of degenerative diseases that often attack the elderly and productive.

Director of Kalbe Farma (KLBF) Sie Djohan said, GENME by Kalbe which has been active since 2017 has proven its existence. GENME continues to be an innovator in providing genetic examination services to support a personalized lifestyle to activities or study plans that play a role in optimizing a person's quality of life.

"In 2017, NutriGENME examination was presented, then SkinGENME was presented in 2018. In 2022, GENME collaborated with Imagene Labs from Singapore in developing two new genetic tests in Indonesia, namely KiddyGENME and PrimeGENME," said Sie Djohan in a written statement, quoted on Monday. June 20.

General Manager of Kalbe Genomics Business Julito Siahaan explained, KiddyGENME is the most complete talent and personality assessment for children's growth and development, based on genetics and a practical approach.

"PrimeGENME as a total solution for predicting aging and assessing the risk of degenerative diseases that may attack the elderly, based on genetics," said Julito.

Julito explained that the KiddyGENME examination includes more than 300 marker genes and provides information on 34 panels of tendencies towards personality, talents, and eating behavior. A total of 34 panels cover impulsivity, empathy, repetitive behavior, sports talent, musical creativity, potential obesity, and others.

"KiddyGENME allows parents to develop their children's full potential in a way that best suits their genetic predisposition," he explains.

While PrimeGENME, he continued, is a genetic examination that includes more than 1.800 marker genes associated with 34 risks of degenerative diseases, including the risk of cataracts, kidney stones, baldness, decreased cognitive function, and sleep disorders.

"These insights provide valuable information on how to design and personalize appropriate lifestyle recommendations, as well as nutritional intake to maintain vitality towards one's golden years," he concluded.